



A future beyond Alzheimer's

Telocyte™ seeks to cure age-
related disease,
starting with Alzheimer's

Legal Disclaimer

The content of this presentation is proprietary and confidential information of Telocyte LLC. It is not intended to be distributed to any third party without the written consent of Telocyte LLC.

Each person who has received a copy of this presentation is deemed to have agreed to not reproduce or distribute this presentation, in whole or in part, without the prior written consent of Telocyte LLC.

Age-related Diseases: A Global Crisis

Governments

"Public health expenditure in EU may grow to 7.7% of GDP in 2070 only on accounts of demographic ageing"
(European Commission, 2021 Ageing Report¹)

Sovereign Wealth

Hevolution Foundation: \$1B annually to fight aging and age-related diseases

"There is not a bigger medical problem on the planet than this one."
(Mehmood Khan, Fund Manager²)



Most Successful Entrepreneurs

Jeff Bezos and Yuri Milner:

\$3B pledged to Altos Labs for cell rejuvenation and fight aging³

Larry Page: \$1.5B for Google's anti-aging California Life Company⁴

Larry Ellison and Peter Thiel:

\$1B for age-related disease and sustainability⁵

¹https://ec.europa.eu/info/sites/default/files/economy-finance/ip148_en.pdf

²<https://www.technologyreview.com/2022/06/07/1053132/saudi-arabia-slow-aging-metformin/>

³<https://www.ns-healthcare.com/news/altos-labs-launches-with-3bn-funding/>

⁴<https://www.technologyreview.com/2016/12/15/69305/googles-long-strange-life-span-trip/>

⁵<https://www.breakoutlabs.org/>

In Focus: Alzheimer's Disease

An age-related disease with no cure

A leading cause of death in adults, about **500,000 per year**¹

Affects **10% over 65** and **50% over 85** in the US²

The global numbers have more than doubled from **1990 to 2016**²

The costliest disease for adults averaging over **\$52k/year/adult**²

¹<https://www.usagainstalzhaimers.org/alzheimers-disease-get-facts>

²<https://curealz.org/the-disease/stats-and-costs/>



Failures

NIH: \$16B

NIH spent over \$16B on Alzheimer's drug solutions since 2008. **All have failed**¹

Biogen \$28B drug debacle

Biogen's disregard of **FDA's decision NOT to endorse the company's Alzheimer's drug Aduhelm** in 2021 compelled the FDA to call for an investigation.

"We have spent more than \$28B in R&D since 2003" (Biogen CEO, 2021)³

Merck's drug failures

No significant new drug for Alzheimer's has been approved in the past 20 years, despite massively expensive trials²

99.6% failure rate

A graveyard for drugs: 1 out of 244 drugs for Alzheimer's disease was approved in 2002-2012, a 99.6% failure rate⁵

Roche Group drug failure

A decade-long clinical trial of a potential Alzheimer's drug failed to prevent or slow cognitive decline, another disappointment in the effort to find solutions for the disease⁴

\$42.5B since '95

Over 2,200 clinical trials, with no cure and no effective therapeutic solution⁶

¹<https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1002/alz.12450>

²<https://www.science.org/content/article/another-alzheimers-drug-flops-pivotal-clinical-trial>

³https://www.biogen.com/en_us/ceo-letter-alzheimers-therapy.html

⁴<https://www.nytimes.com/2022/06/16/health/alzheimers-drug-crenezumab.html>

⁵<https://www.scientificamerican.com/article/why-alzheimer-s-drugs-keep-failing/>

⁶<https://www.wsj.com/articles/lack-of-optimism-for-alzheimers-trials-means-theres-little-to-lose-11663121287>

Progress? Not so fast.

Biogen & Eisai recently announced¹ that their drug Lecanemab appeared to slow down Alzheimer's

- Results come after the failure of the companies' drug Aducanumab
- Clinical trials based on outdated small molecule drugs strategy and too short a time frame
- Lecanemab is unlikely to produce a different disease outcome from the fatal one we see 100%
- Drug effect is to help suppress the symptoms, equivalent to using a cough suppressant to treat a virus infection such as the recent pandemic
- Alzheimer's and CNS is addressed by Telocyte with
 - next generation biologic clinical methods
 - superior gene therapy techniques with faster routes for clinical evaluation
 - reduced program cost and much shorter development timescales



Regrettably, Eisai recently published that Lecanemab has likely contributed to a patient's death²

¹<https://apnews.com/article/health-2e51397597577d49d6d5f82bc0042871>

²<https://www.fiercebiotech.com/biotech/lecanemab-may-have-contributed-patient-death-report>

Telocyte Mission




Disrupt
global
healthcare and
the
pharmaceutical
industry with
telomerase
therapy



Reverse
age-related
diseases starting
with Alzheimer's



Deliver
preventative
and therapeutic
healthcare via AI
and Big Data
driven Virtual
Diagnostic
Clinics



Telocyte Disruption

Only biotech company addressing Alzheimer's and age-related diseases using the Telomerase protocol & AI Therapeutics



TELOMERASE INNOVATION

The first and only
**Human Telomerase
Protocol** to cure human
age-related diseases



AI THERAPEUTICS

Ethical AI+VR: deliver a holistic
therapeutic **precision preventative
care**, and substantially **reduce clinical
costs**



EXPERTISE

Telocyte is founded by **Dr. Michael Fossel**, the world's leading expert on cellular aging and age-related diseases



KNOWLEDGE PLATFORM

Telocyte's innovative knowledge **strategy** ensures effective, secure, and compliant clinical execution, as well as enabling the advent of digital similars in life sciences

Telomerase Origins

**Elizabeth
Blackburn²**

Isolates and describes
the telomerase enzyme



1974

1981



Calvin Harley
CSO, GERON^{4,5,6}

Telomerase resets aging in
human cells and tissues



1997

1998



**Blackburn,
Greider, Szostak⁸**

2009 Nobel Prize for the
discovery of telomerase



2004

2009




Michael Fossel
Founder of Telocyte¹⁰

Telomerase protocol for age-
related diseases



2012

2020



**Alexey
Olovnikov¹**


First prediction of
telomerase existence and
link to aging and cancer

Michael Fossel³

First articles (in *JAMA*)
on the potential to treat
age-related disease with
telomerase

Michael Fossel
Clinical Medicine Expert,
GERON^{6,7}

Clinical telomerase protocol with
Calvin Harley



Maria Blasco⁹

Telomerase delays
aging in mice

¹https://en.wikipedia.org/wiki/Alexey_Olovnikov

²https://en.wikipedia.org/wiki/Elizabeth_Blackburn

³<https://doi.org/10.1001/jama.1997.0355016006504>

⁴<https://pubmed.ncbi.nlm.nih.gov/9454332/>

⁵<https://pubmed.ncbi.nlm.nih.gov/11850774/>

⁶<https://pubmed.ncbi.nlm.nih.gov/12663456/>


⁷<https://jamanetwork.com/journals/jama/article-abstract/187604>

⁸<https://www.nobelprize.org/prizes/medicine/2009/summary/>

⁹<https://www.embopress.org/doi/full/10.1002/emmm.201200245>

¹⁰<https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.12012>


Telomerase Evolution




Validation in Animals

Telomerase is proven to reverse the aging process in animal studies, resulting in improved behavioral^{1,2,3}, musculoskeletal², and cardiovascular² function


Lifespan Increases²




Physiology Improves²



Behavior Improves²



Telomerase increases neural stem cell proliferation and differentiation^{1,3}



¹<https://pubmed.ncbi.nlm.nih.gov/21211774/>

²<https://www.embopress.org/doi/full/10.1002/emmm.201200245>


³<https://doi.org/10.1038/nature09603>

Validation in Human Cells/Tissues

Human cells

Fibroblasts¹: *Science*, 1998

Neurons²: *J Neuroscience*, 2015



Human tissues

Skin³: *Exp Cell Res*, 2000


Bone⁴: *J Bone Mineral Res*, 2001

Cardiac Vessels⁵: *Circ Res*, 2001

Medical textbooks

- *Cells, Aging, and Human Disease*
Oxford University Press
Michael Fossel, 2004

- *Aging: How aging works, how we can reverse aging, and prospects for curing aging diseases*
Academic Press
Michael Fossel, 2024



¹<https://www.science.org/doi/10.1126/science.279.5349.349>

²<https://www.jneurosci.org/content/35/4/1659>

³<https://pubmed.ncbi.nlm.nih.gov/10896778/>

⁴<https://pubmed.ncbi.nlm.nih.gov/11499868/>

⁵<https://doi.org/10.1161/hh2101.098443>

Reverse Aging

Telocyte's proprietary telomerase-based protocol will reverse cell aging in humans, curing age-related diseases

As cells age, telomeres shorten and cells become dysfunctional, resulting in age-related diseases. The telomerase protocol restores a younger pattern of gene expression and normal cell function. Telocyte's solution brings telomerase to humans.



<https://www.tasciences.com/telomeres-and-cellular-aging.html>

Telocyte Products

Therapeutic

Proprietary telomerase-based protocol will reverse cell aging, curing age-related diseases

Knowledge Platform

- Blockchain, data provenance
- Built-in governance and compliance (HIPAA, OHRP, FDA)
- Identity, data ownership, dynamic consent
- Federated AI
- Support decentralized clinical trials

Telocyte Therapeutic



Health Data Platform

AI Therapeutics

AI Therapeutics

- AI-enhanced diagnostics
- Alerting and signaling
- Personalized therapeutics
- Pre-treatment targeting
- Treatment outcome prediction



Telocyte Proprietary Protocol

The First and Only Human Telomerase Protocol

Dose: Adjusted to patient's body/brain weight

Route: Carefully chosen for safety & efficacy

Vector & Plasmid: Optimized to target cells

FDA Compliant¹: Rigorous & credible

Human Protocol FDA BLA compliant¹			Pretrial	Day 1	Week 1	Week 4	Month 2	Month 4	Month 6
Therapy	Treatment	TEL-01							
	Procedure	ICM injection							
Evaluation	Clinical	Interview							
		Physical Exam							
Trial Data	Cognitive	MMSE, ADAS-Cog, etc.							
	Laboratory	Misc. (UA)							
		Blood							
		CSF							
	Imaging	PET/MRI							

General targets

- All aging, dysfunctional cells


Specific targets

• Alzheimer's (CNS):

Neurons
Microglia
Astrocytes

• Cardiovascular Disease:

Vascular cells
Cardiac myocytes
Fibroblasts



¹<https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber>

Knowledge Platform

DATA AS AN ASSET


- Secure data exchange network and custody of user's digital assets
- Identity management and verification capabilities, dynamic consent
- Auditability and data provenance authentication via hybrid blockchain
- Data trust and quality persistence

COMPLIANCE

- Built-in governance and compliance for healthcare data (HIPAA, OHRP, FDA)
- Integration with EMRs, CROs, partners, and government platforms, 21 CFR 11 compatible

DATA SOURCE AND INTEGRATION

- Healthcare data (EHR, clinical)
- Biometrics data (real-time, historical)
- Lifestyle, contextual, and financial data
- Consumer, social, and impression data
- Daily data through VR interaction and capture



ANALYTICS & AI

- Therapeutic program personalization
- Digital similars
- Treatment outcome prediction
- AI for diagnostics, monitoring, virtual healthcare
- Derived data through federated AI for marketplace participation and services

PROGRAM SUPPORT

- Clinical decision support
- Accelerate therapeutic deployment
- Cost reduction through AI-based clinical optimization
- AI-enhanced therapeutic population targeting

CUSTOMER VALUE

- User engagement and loyalty through privacy and earned trust
- Therapeutic and lifestyle care using AI and VR platform
- Health assessment and monitoring for holistic and precision preventative care


Data Strategy

Traceability & Compliance

- Hybrid blockchain platform
- Operational data network
- Built-in compliance
- Access management and control
- Auditable API integration with clinical endpoints
- Indisputable record of clinical results

Personalization

- Hyper-personalization
- Granular consent
- Health knowledge platform
- Increased patient engagement and participation in trials and preventative care



Clinical Cost Reduction

- Data compliance and architecture yields over 30% cost reduction of expenses and time in clinical trial expenses, worth \$ billions in later trial phases

Digital DNA

- Digital graph with trust and context built in captures all patient data, relationships, and events
- Multi-source data validation increases the quality and value of the data

AI Therapeutics & VR Clinic

Virtual Personalized Care

- Ethical AI+VR
- Personalized therapeutic program
- Preventative care, alerting
- Health assessment and outcome prediction via continuous learning

Extend Support Circle

- Remote patient monitoring reduces hospitalizations¹
- Remote medication management
- Personal healthcare assistance
- Virtual visits

Trust and value

- HIPAA and FDA compliant
- Secure and safe
- Personalization
- Ethical and compliant AI

E-Learn & Engage

- Educate about age-related diseases and preventative care
- Information on decentralized clinical trials



¹<https://blog.amchealth.com/can-telemonitoring-reduce-hospitalization-and-cost-of-care-a-health-plans-experience-in-managing-patients-with-heart-failure>

Endorsements for Telocyte



"Dr. Fossel's unwavering dedication to unraveling the pathogenesis of neurodegenerative diseases led him to conceive both a unified model and a novel gene therapy with the potential to become the first agent to alter the course of neurodegenerative diseases such as Alzheimer's.

Telocyte's telomerase gene therapy will restore hope to Alzheimer's disease patients. Applications to other neurodegenerative conditions such as Parkinson's and age-related diseases (e.g., cardiovascular, renal, osteoarthritis) will follow."

S. Nagendran MD

President of R&D and Chief Medical Officer, Jaguar Gene Therapy



"Dr. Fossel has set out a new model for dementia and age related brain dysfunction which presents a unifying theory [...] and potentially of an exciting new approach to disease causation and hence treatment.

His in-depth analysis is intellectually compelling and takes account of a wide range of experimental data from several fields. Dr. Fossel's work presents radical new ideas and is extremely exciting."

Sir Edward Byrne

**AC FmedSci FTSE FAHMS
MD DSc FRCP FRACP**

Vice Chancellor Monash University
President King's College

Vice Chancellor's Distinguished fellow ANU
Emeritus Professor of Neurology King's College



"Dr. Fossel offers us a logical and potentially effective point of intervention for Parkinson's, Alzheimer's disease and other age-related neurodegenerative diseases. His model calls for clinical testing – rigorously and credibly – as his approach may well be the most promising approach that we have seen in decades.

I heartily and unreservedly recommend him for the Breakthrough Prize in Life Sciences."


Z. Khachaturian PhD

President of Campaign to Prevent Alzheimer's, former editor-in-chief Alzheimer's & Dementia, Journal of the Alzheimer's Association

Competitive Landscape

Companies are targeting the symptoms

β Amyloid




Eli Lilly
Biogen
Alzheon
Vivoryon
Wren Therapeutics
Yumanity
AC Immune SA
Denali Therapeutics
Priaboid

Tau




Voyager
Therapeutics
AC Immune SA
Denali Therapeutics
Priaboid

Inflammation



TBD Therapeutics


Mitochondria



Alector
Amylyx Pharma
Codiak BioSciences
Oracion Biotech
Tetra

Telocyte is targeting the underlying cause

Telomerase



TELOCYT

Market Opportunity

\$2.8T

CNS

Central Nervous System

Alzheimer's

- global therapeutics market \$4B in 2021
- growing at a CAGR of 16.2%
- **global costs \$1.7 trillion by 2030¹**

Parkinson's

- **global costs over \$51B by 2030²**

Other Dementias

- **global MS costs \$84B in 2030³**
- **other Dementia costs \$800B by 2030⁴**

\$1.0T

CVD

Cardiovascular Disease

- global CVD drug market: \$48B
- projected to reach \$64B by 2026
- growing at a CAGR of 3.8%
- **global costs to reach \$1.0T by 2035**

Myocardial Infarction

Carotid Artery Disease

Congestive Heart Failure

++

+

Other

Osteoarthritis

Osteoporosis

Pulmonary fibrosis

Renal failure

Immunosenescence

¹<https://www.alzint.org/about/dementia-facts-figures/dementia-statistics/>

²<https://rdcu.be/cUFE0>

³<https://n.neurology.org/content/98/18/e1810>

⁴<https://www.rand.org/capabilities/solutions/planning-for-the-rising-costs-of-dementia.html>

Strategy

OBJECTIVE

Telocyte brand dominance in age-related and preventative Healthcare

TARGET MARKET

Age-related disease, beginning with Alzheimer's (7M in US in 2028, 60M+ worldwide)

VALUE

An affordable and effective Telomerase Gene Therapy as a 5-yearly vaccination for Alzheimer's and age-related diseases

DISTRIBUTION

Licensing agreements with NHS and Big Pharma, covering the costs of servicing the Alzheimer's global population



PRICING

Initial pricing: 40% of the US 5-year patient cost of Alzheimer's, approx. \$104,600/dose

REVENUE

\$52B over the first 10 years through licensing (5% royalty)

INTEREST

NHS UK, Eli Lilly, Jiangsu Province, China, GemVax, South Korea

GROWTH

- Target population increase (2x-3x)
- VR Clinic + AI: increase SAM
- Distribution + AI: Increase Adoption

Revenue

Initial Price: \$104,600/dose (40% of 5-year Alzheimer's cost/person)


Licensing Royalty: 5% of net sales

Target Population (TAM): 7M US, 50M globally, to grow 2x to 3x²

Serviceable Population (SAM): 10% of TAM initially

Year	TAM US AD	TAM World AD	SAM US	SAM World
2028	7,000,000	58,000,000	700,000	0
2029	7,750,000	63,000,000	2,976,000	0
2030	8,500,000	68,000,000	3,264,000	8,993,000
2031	9,250,000	73,000,000	3,552,000	14,481,375
2032	10,000,000	78,000,000	3,840,000	20,631,000
2033	10,750,000	83,000,000	4,128,000	27,441,875
2034	11,500,000	88,000,000	4,416,000	34,914,000
2035	12,250,000	93,000,000	4,704,000	43,047,375
2036	13,000,000	98,000,000	4,992,000	51,842,000
2037	13,750,000	103,000,000	5,280,000	61,297,875
2038	14,500,000	108,000,000	5,568,000	71,415,000

Revenue Growth Projection (2028-2038)



Year	SAM US	SAM World	Adoption US	Adoption World	Price	Royalty
2028	700,000	0	0.66%	0.00%	\$104,600	5%
2029	2,976,000	0	1.48%	0.00%	\$99,370	5%
2030	3,264,000	8,993,000	2.17%	0.66%	\$94,140	5%
2031	3,552,000	14,481,375	2.86%	1.48%	\$88,910	5%
2032	3,840,000	20,631,000	3.55%	2.17%	\$83,680	5%
2033	4,128,000	27,441,875	4.24%	2.86%	\$78,450	5%
2034	4,416,000	34,914,000	4.93%	3.55%	\$73,220	5%
2035	4,704,000	43,047,375	5.62%	4.24%	\$67,990	5%
2036	4,992,000	51,842,000	6.31%	4.93%	\$62,760	5%
2037	5,280,000	61,297,875	7.00%	5.62%	\$57,530	5%
2038	5,568,000	71,415,000	7.69%	6.31%	\$52,300	5%

Revenue projections with Total Addressable Market (TAM), Service Addressable Market (SAM), and Adoption estimates³

¹<https://invivo.pharmaintelligence.informa.com/IV146643/Strategies-To-Encourage-Universal-Access-To-Gene-Therapies>

²<https://www.who.int/news-room/fact-sheets/detail/ageing-and-health>

³<https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf>

Gene Therapy Valuations

COMPANY	PURCHASER	DEAL VALUE	DRUG/TARGET
AveXis	Novartis	\$8.7B	Zolgensma - Spinal Muscular Atrophy
Spark Therapeutics	Roche Holdings	\$4.8B	Luxterna - Genetic Retinal Diseases
Audentes Therapeutics	Astellas Pharma	\$3.0B	Neuromuscular Diseases
Brammer Bio	Thermo Fisher	\$1.7B	Viral Vectors for Gene Therapy
AskBio	Bayer	\$4.0B	Neuromuscular, CNS, and Others
Sarepta Therapeutics	Roche Holdings	\$1.2B	Duchene Muscular Dystrophy, etc.
Paragon Bioservices	Catalent	\$1.2B	AAV & Plasmids for Gene Therapy


The Journey

Partnerships

- Strategic partners for clinical trials: Houston Methodist
- Strategic partners for drug manufacturing and CRO services: Thermo Fisher
- Strategic partners for the build and operation of the data and technology platform
- Strategic partners for VR Clinic

Inception

- Founded in 2015 by Michael Fossel, MD, PhD, the leading expert on cell aging and age-related disease
- Seed investment of \$600k



Team

- Strong management team
- Globally recognized scientists, clinicians, and gene therapy experts on Scientific & Clinical Advisory Boards adding rigor and global credibility in protocol design and execution
- Accomplished Business and technical advisors

IP and Compliance

- Cleared legal/IP search
- Independent gap analysis by a global CRO confirmed readiness for FDA and regulatory trials
- Clinical trial protocol validated and peer-reviewed

Licensing Bidders

- Eli Lilly
- NHS UK
- GemVax
- Jiangsu Province, China

Multi Phased Roadmap

- Company Formation
- Executive Team and Advisory Board
- IP Search, FDA Compliance¹
- IP and Proprietary Strategy
- Partnerships for Clinical Trials, Data Platform, Drug Manufacturing
- Drug Discovery Execution Plan
- Drug Discovery Technology Mandate and Requirements
- Technology Product verticals, Strategy, and Budget
- Knowledge Platform Design and Architecture
- AI Therapeutics Vision and Strategy: Telocyte Clinics Design and Architecture
- Tengrium™ Technology: Health Data Bank and Blind AI Model Training
- Contractual Relationships and Strategic Partnerships
- IP and Legal Counsel Team
- Drug Manufacturing
- Dosing, Distribution, Safety, and Toxicity Data
- Therapeutic IP Technology Platform Development
- Animal Studies
- Trial Results and Data Analysis
- Initial FDA Feedback
- Knowledge Platform Development Design and Architecture
- AI Therapeutics Prototyping and Development: Smart Learning, Digital Twin, Tengrium™ Platform
- IP Generation and Documentation
- Continue Animal Trials, Large Mammals
- File for FDA Phase 1 Human Trial
- Manufacture of the Gene Therapy Product for FDA Phase 1 Human Trial
- File IP on Animal and human Protocols
- Therapeutic IP Technology Platform First Prototype
- Health Data Platform: Knowledge Platform Prototype
- VR Clinic Prototype
- Smart Learning Platform Prototype
- Digital Twin Platform Prototype
- Proprietary AI & Therapeutic Technologies Prototype
- Begin FDA Phase 1 Human Trial
- Full Animal Studies Analysis, IP, and Data Vault
- Therapeutic IP Technology Platform Alpha in Production
- Knowledge Platform Development Design and Architecture Alpha in Production
- AI Therapeutics Alpha in Production: Tengrium™ Technology: Health Data Bank and Blind AI Model Training
- Telocyte Clinic Alpha with VR Clinic in Production
- Smart Learning Platform and Digital Twin Platform Alpha in Production
- Proprietary AI & Therapeutic Technologies in Production
- Complete FDA Phase 1 Human Trials
- Begin FDA Phase 2 Human Trial
- Increased Valuation from Proven Human Efficacy
- Launch VR Clinic
- Enhanced Diagnostics and Personalized Treatment Optimization
- AI Therapeutics in Production: Tengrium™ Technology: Health Data Bank and Blind AI Model Training with Hybrid AI + Expert Layer
- Telocyte Clinic With AI Therapeutics in Production
- Smart Learning Platform and Digital Twin Platform Integration with Diagnostics



¹<https://www.fda.gov/vaccines-blood-biologics/development-approval-process-cber/biologics-license-applications-bla-process-cber> 26

Next Steps

In partnership with Houston Methodist, a leading neurosciences clinical trial institution, to carry out simultaneous Telocyte CNS and CVD studies to permit human trials.

Animal study

Objective: obtain efficacy, distribution, and toxicity data

Protocol: Houston-based 6-month study of 12 aged animals


Measures: imaging, labs, cognitive performance, etc.

Human trials

Objective: obtain FDA safety and efficacy data in phase 1 trial

Protocol: US-based 6-month study of 12 patients with moderate Alzheimer's

Measures: imaging, labs, cognitive testing, etc.



<https://www.houstonmethodist.org/>

Executive Team



Michael Fossel MD, PhD
Founder, CMO

The [leader](#) in proposing the use of telomerase to treat age-related human disease, he has an MD and PhD in Neurobiology from Stanford University, was a clinical professor of medicine for almost three decades, and authored both *The Telomerase Revolution* (which the *Wall Street Journal* named as one of the best science books of 2015) and the Oxford University Press textbook, *Cells, Aging, and Human Disease*.

Therapeutics



Peter Rayson
Founder, CEO

An experienced industry executive, Rayson provides leadership and business acumen for Telocyte. His background includes engineering management with Computer Vision Inc., as well as working with Rolls Royce Aerospace, Airbus, Ford, Jaguar Land Rover. He was the Associate Director of the Technology Innovation Center at Birmingham, UK but stepped down in 2011 when his mother was diagnosed with dementia.

Business



Rajesh Shukla, PhD
CSO

Rajesh brings over 30 years of entrepreneurial biotechnology expertise with clinical and medical strategy, with over \$300M in funding. Rajesh leads gene therapy clinical development leveraging discovery through registrational expertise in Neurology, Immunology, Infectious Diseases, Oncology, Surgical reconstruction, Asthma and Anaphylaxis clinical programs, with senior positions at Integra LifeSciences, Castle Creek Biosciences (VP, R&D), Motif Biosciences (VP), Acorda therapeutics (Sr Medical Director), Pfizer (Sr Director & R&D Head), Teva and Bristol-Myers Squibb.

Drug Development



Michelle Hylan
COO

Michelle Hylan is an internationally experienced **Clinical Research Executive** with demonstrated success partnering with clients to optimize clinical program outcomes through alignment of business strategy, processes, and org composition, as well as bringing biotech start-ups from proof of concept to IPO. Michelle has focused on advancing unique science solutions to address unmet medical needs. She has broad experience in industry best practices on global program, clinical, and quality management. She specializes in strategic development and implementation, clinical trial design, CRO/vendor selection and management.

Clinical Operations



Georgi Gospodinov, PhD
CTO

An executive, advisor, and investor, offering thought leadership and innovative ideas, Georgi has led the engineering and analytics teams of multiple enterprises to deliver strategic product vision, tech resource hire and management, enterprise security, architecture, and integration. He has managed product delivery and driven innovation in data and technology, directly contributing to the design and implementation of product.

Technology & AI



Radomir Julina, PhD
CPO

Prior to his current role as Managing General Partner at Pharma Capital Partners, Radomir was head of New Molecular Entity Planning at Roche and ran an Alzheimer's drug clinical trial through Phase III. He has worked in pharmaceutical, biotech and private equity for the last 25+ years. He was Managing Director at Celtic Pharma Management, a spin-off from Hoffmann-La Roche. He holds a Ph.D. in Organic Chemistry from the University of Zurich and has a passion for drug development, building virtual organizations and investment finance

Clinical Strategy

Board of Directors



Michael Fossel MD, PhD
Board Member

The [leader](#) in proposing the use of telomerase to treat age-related human disease, he has an MD and PhD in Neurobiology from Stanford University, was a clinical professor of medicine for almost three decades, and authored both *The Telomerase Revolution* (which the *Wall Street Journal* named as one of the best science books of 2015) and the Oxford University Press textbook, *Cells, Aging, and Human Disease*.

Therapeutics



Peter Rayson
Chairman of the Board

An experienced industry executive, Rayson provides leadership and business acumen for Telocyte. His background includes engineering management with Computer Vision Inc., as well as working with Rolls Royce Aerospace, Airbus, Ford, Jaguar Land Rover. He was the Associate Director of the Technology Innovation Center at Birmingham, UK but stepped down in 2011 when his mother was diagnosed with dementia.

Business



Mark Hodges
Board Member

An experienced technology executive, Hodges provides effective and inspiring leadership for all Telocyte programs and services. His background includes executive experience in the aerospace and defense industries, CAD business development, including at Computer Vision with Peter Rayson. He was the General Manager of China Operations, where he managed 500 engineers across 15 offices for PTC Inc., a listed Boston engineering software firm.

Operations

Technical Advisory Board

Professional expertise: gene therapy, telomerase, clinical trial design, and neurological disease



Mimoun Azzouz, PhD



Joseph Araujo



Suzanne Hendrix, PhD



Kurt Whittemore, PhD



Mario Masellis, MD



Steven Arnold, MD



Russell Swerdlow, MD






Strategic Investment & Partnership

Strategic investors:

- ❑ Invest \$50M in Telocyte to support Phase 2 milestones
- ❑ Take care of Telocyte's clinical trials costs in return for equity
- ❑ Collaborate with Telocyte and take care of AI and Knowledge Platform development costs in return for equity
- ❑ Build and operate Telocyte business in the US and UAE

Books Authored by Dr Michael Fossel





A FUTURE BEYOND ALZHEIMER'S

www.telocyte.com

